Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Sanofi's Distribution Center in Quebec, Canada

Immunology and inflammation

Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners.

September 5, 2025

2 min read

Tristan Manalac

China

Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+

Hengrui Pharmaceuticals has been busy this year, signing a nearly $2 billion cardio contract with Merck in March and a 12-asset agreement with GSK in July worth up to $12 billion.

September 5, 2025

2 min read

Tristan Manalac

HIV

Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries

In coordination with the United States President’s Emergency Plan for AIDS Relief, Gilead will make its twice-yearly HIV prophylactic Yeztugo available to resource-limited countries “at no profit.”

September 5, 2025

1 min read

Tristan Manalac

halftone magazine style banner, dislike, negative rating, hand thumbs down

FDA

FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access

Perhaps the most interesting of the pile of FDA rejection letters was for Lykos Therapeutics’ MDMA therapy. Letters sent to Stealth BioTherapeutics, Regeneron and more were also released as the agency also promised future CRLs “promptly after they are issued to sponsors.”

September 4, 2025

4 min read

Annalee Armstrong

2006 James Gathany Captured by James Gathany, Centers for Disease Control's biomedical photographer, this 2006 image depicted the exterior of the new "Tom Harkin Global Communications Center", otherwise known as Building 19, located on the organization's Roybal Campus in Atlanta, Georgia. The facility houses the CDC's Information Center/Library, auditoria and meeting halls, which are used to accommodate in-house staff meetings, and national/international conferences hosted by the CDC, and the National Center for Health Marketing's, Division of Creative Services, which includes a full service television broadcast facility. The exhibit area currently features the "Global Symphony", the first of several permanently installed exhibitions, and changing exhibitions that focus on a variety of public health topics. The exhibits in the Center are self-guided, and require no advance reservations. Additional curriculum-based exhibits and programming will be added in the future. Tom Harkin Global Communications Center Exhibit Area Centers for Disease Control and Prevention - 1600 Clifton Road, N.E., Atlanta, Georgia 30333 - Hours: Monday Friday, 9 am 5 pm, except for federal holidays Admission is free - Government-issue photo ID is required for entry. Please note that CDC is a working federal facility and as such does not provide public tours of its campus and laboratories. - For more information please call 404-639-0830.

CDC

ACIP Revamp Continues as Kennedy Eyes Seven New CDC Vaccine Advisors

The new additions would bring ACIP membership to 14 total. Several of the proposed members have taken part in anti-vaccine activity or made anti-vaccine statements.

September 4, 2025

2 min read

Dan Samorodnitsky

Illustration showing two hands holding objects on scales

Job Trends

Silver Linings: When Getting Laid Off Has an Upside

Generous severance packages, getting out of toxic workplaces and finding a better job with better pay are a few reasons respondents to a recent BioSpace survey felt that being laid off was for the best.

September 4, 2025

5 min read

Angela Gabriel

IN PARTNERSHIP WITH TACONIC BIOSCIENCES

The ‘Research Safety Net’ Saving Scientists from Funding Crisis

In this episode presented by Taconic Biosciences, BioSpace’s head of insights Lori Ellis discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment with Mike Garrett, CEO.

September 4, 2025

1 min read

Lori Ellis

Layoffs

AC Immune Downsizes by 30%, Narrows Pipeline Focus

The reprioritization effort will help AC Immune extend its cash runway through the third quarter of 2027.

September 4, 2025

2 min read

Tristan Manalac

Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.

Regulatory

‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework

While the new framework signals continued flexibility at the FDA regarding rare disease approvals, some analysts and advocates question what tangible impacts the new guidelines will have.

September 4, 2025

2 min read

Tristan Manalac

Visit website

Email Us

IN THE PRESS

Press Releases

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

June 2, 2025

4 min read

BioMidwest

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings